7h agoThe FlyBULLISH 64General
Archived explainer. For the current picture see today's ORKA page.
Why Is ORUKA THERAPEUTICS I (ORKA) Stock Up Today?
By the Top Tier Newswire AI Desk · October 26, 2026 at 11:46 AM ET · reviewed against 8 wire stories
ORUKA THERAPEUTICS I (ORKA) is up +13.55% in the latest session. Our newswire has captured 8 stories on ORKA across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Oruka Therapeutics shares surged 13.55% to close at $91.01 on Monday. The primary driver was the announcement of positive Week 16 data from the ongoing EVERLAST-B trial for its lead candidate, ORKA-001, in moderate-to-severe plaque psoriasis.
What Happened
Oruka Therapeutics reported that 61% of patients in the high-dose 600 mg group achieved a PASI 100 response, while 86% achieved a PASI 90 response. The company noted that these results are highly similar to those from the earlier EVERLAST-A trial and that the safety and tolerability profile remains consistent with the IL-23p19 class. The company filed a Form 8-K with the SEC on October 26, 2026, to disclose these regulatory updates. Guggenheim reiterated its rating on the stock following the release of this trial data. The company stated that ORKA-001 is on track to advance into Phase 3 trials in the first half of 2027.
What The Data Shows
The stock opened at $79.51, representing a 0.8% gap down from the prior close of $80.15. It traded as low as $78.00 at 7:05 AM ET before climbing to a session high of $91.58 at 10:00 AM ET. Volume stood at 0.5 million shares, which is 0.5 times the three-month daily average. The move pushed the stock to print 16 fresh 52-week highs on October 26, 2026. The current price sits within the 52-week range of $25.23 to $115.52. The company has a market capitalization of $5.3 billion and remains unprofitable with a trailing twelve-month EPS of $2.02. Over the last 8 sessions, the stock had been relatively flat, moving 0.4% from $80.35 to $80.07. Recent insider activity includes 16 sales totaling $22.0 million over the last 90 days, with no recorded buys. Specific recent sales include $706,735 by Paul T. Quinlan on October 20, 2026, and sales by Joana Goncalves and Arjun Agarwal in mid-October.
What To Watch
The company is on track to advance ORKA-001 into Phase 3 trials in the first half of 2027.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ORKA by the numbers
Last: $91.01Session: +13.55%7 sessions: -0.35%Coverage: 8 stories / 6 sourcesAI sentiment: 60/100 (bullish)Mkt cap: $5.3B52w: $25.23 to $115.52
The headlines behind the move
7h agoInvesting.com Analyst RatingsNEUTRAL 52Analyst
Guggenheim reiterates Oruka Therapeutics stock rating on trial data
Guggenheim reiterates Oruka Therapeutics stock rating on trial data
9h agoTipRanksBULLISH 74Product/PR
Oruka Therapeutics Reports Strong Phase 2b Psoriasis Results
Oruka Therapeutics ( ($ORKA) ) has shared an update. Oruka Therapeutics, Inc. is a clinical-stage biotechnology company focused on novel biologics for chronic infla...
9h agoSEC 8-KNEUTRAL 50General
Oruka Therapeutics, Inc. (ORKA) files 8-K
Filed: 2026-10-26 AccNo: 0001213900-26-112281 Size: 18 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
10h agoThe FlyBULLISH 58Product/PR
Oruka Therapeutics announces results from EVERLAST trial of ORKA-001
10h agoBusiness InsiderBULLISH 74Product/PR
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class
1d agoBusiness InsiderNEUTRAL 53Product/PR
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic...
1d agoGlobeNewswireNEUTRAL 53Product/PR
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ORKA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ORKA move explainers: 2026-10-26 · 2026-09-23